Safety, tolerability, and efficacy of repeated doses of dihydroartemisinin-piperaquine for prevention and treatment of malaria: a systematic review and meta-analysis

Julie Gutman, Stephanie Kovacs, Grant Dorsey, Andy Stergachis, Feiko O Ter Kuile, Julie Gutman, Stephanie Kovacs, Grant Dorsey, Andy Stergachis, Feiko O Ter Kuile

Abstract

Background: Intermittent preventive treatment (IPT) for malaria is used in infants, children, adults, and pregnant women. Dihydroartemisinin-piperaquine (DP) is an effective, well tolerated artemisinin-based combination therapy. The long half-life of piperaquine makes it attractive for IPT. We conducted a systematic review and meta-analysis to establish the efficacy and safety of repeated treatment with DP.

Methods: Following PRISMA guidelines, we searched multiple databases on Sept 1, 2016, with the terms: "human" AND "dihydroartemisinin-piperaquine" OR "DHA-PPQ". Studies were eligible if they were randomised controlled trials (RCTs) or prospective cohort studies involving repeat exposures to standard 3-day courses of DP for either seasonal malaria chemoprevention, mass drug administration, or treatment of clinical malaria, conducted at any time and in any geographic location. Random-effects meta-analysis was used to generate pooled incidence rate ratios and relative risks, or risk differences.

Findings: 11 studies were included: two repeat treatment studies (one in children younger than 5 years and one in pregnant women), and nine IPT trials (five in children younger than 5 years, one in schoolchildren, one in adults, two in pregnant women). Comparator interventions included placebo, artemether-lumefantrine, sulfadoxine-pyrimethamine (SP), SP+amodiaquine, SP+piperaquine, SP+chloroquine, and co-trimoxazole. Of 14 628 participants, 3935 received multiple DP courses (2-18). Monthly IPT-DP was associated with an 84% reduction in the incidence of malaria parasitaemia measured by microscopy compared with placebo. Monthly IPT-DP was associated with fewer serious adverse events than placebo, daily co-trimoxazole, or monthly SP. Among 56 IPT-DP recipients (26 children, 30 pregnant women) with cardiac parameters, all QTc intervals were within normal limits, with no significant increase in QTc prolongation with increasing courses of DP.

Interpretation: Monthly DP appears well tolerated and effective for IPT. Additional data are needed in pregnancy and to further explore the cardiac safety with monthly dosing.

Funding: Bill & Melinda Gates Foundation and NIH.

Copyright © 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license. Published by Elsevier Ltd.. All rights reserved.

Figures

Figure 1
Figure 1
PRISMA flow chart DP=dihydroartemisinin-piperaquine. AL=artemether-lumefantrine. A second trial reporting on the use of DP for rescue treatment among pregnant women included nine women who received at least two courses of DP (six received three courses and three received two courses), but all women had also received a preceding course of either quinine or intravenous artesunate with or without clindamycin, and there were no control women who had not received DP. *One trial comparing seasonal malaria chemoprevention (SMC) with sulphadoxine-pyrimethamine plus amodiaquine vs placebo SMC (passive case detection and case management with either DP or AL during the malaria transmissions season) was excluded because only 27 of 800 children (3·4%) in placebo SMC group (ie, the DP case management group) received two or more courses of DP and safety data by number of courses received were not available.
Figure 2
Figure 2
Pooled incidence rate ratio for any parasitaemia, monthly dihydroartemisinin-piperaquine vs placebo DP=dihydroartemisinin-piperaquine. PYAR=person-years at risk. IR=incidence rate. IRR=incidence rate ratio. Lwin and colleagues and Zongo and colleagues did not report PYAR, instead they reported cumulative incidence over a year. PYAR was calculated based on the incidence rate and number of events. Zongo and colleagues' numbers are based on intent to treat.
Figure 3
Figure 3
Pooled incidence rate ratio or relative risk for any parasitaemia, monthly dihydroartemisinin-piperaquine vs any other therapy DP=dihydroartemisinin-piperaquine. PYAR=person-years at risk. IR=incidence rate. IRR=incidence rate ratio. CTX=co-trimoxazole. SP=sulfadoxine-pyrimethamine. SP+PQ=sulfadoxine-pyrimethamine piperaquine. SP+AQ=sulfadoxine-pyrimethamine amodiaquine. AL=artemether lumefantrine. Lwin and colleagues and Zongo and colleagues did not report PYAR. PYAR was calculated based on the incidence rate and number of events. Cisse and colleagues reported cumulative incidence. Kakuru reported detection of malaria parasites by LAMP at each visit as the prevalence of positive tests during pregnancy out of all tests. Zongo and colleagues' numbers are based on intention to treat.
Figure 4
Figure 4
Pooled odds ratios for any serious adverse event after exposure to dihydroartemisinin-piperaquine stratified by comparator therapy DP=dihydroartemisinin-piperaquine. SAE=serious adverse event. CTX=co-trimoxazole. IPT=intermittent preventive treatment. IST=intermittent screening and treatment. SP=sulfadoxine-pyrimethamine. SP+PQ=sulfadoxine-pyrimethamine piperaquine. SP+AQ=sulfadoxine-pyrimethamine amodiaquine. SP+CQ=sulfadoxine-pyrimethamine chloroquine. AL=artemether-lumefantrine. Zongo and colleagues' numbers are based on actual drug exposures. Poespoprodjo and colleagues: only 64 of 408 DP recipients received two or more courses of DP, but information of SAEs by number of courses received was not available.
Figure 5
Figure 5
Pooled odds ratios for death after exposure to repeated courses of dihydroartemisinin-piperaquine stratified by comparator therapy Comparisons with zero events in both groups were excluded from the analysis of the pooled OR. OR=odds ratio. DP=dihydroartemisinin-piperaquine. CTX=co-trimoxazole. IPT=intermittent preventive treatment. IST=intermittent screening and treatment. SP=sulfadoxine-pyrimethamine. SP+PQ=sulfadoxine-pyrimethamine piperaquine. SP+AQ=sulfadoxine-pyrimethamine amodiaquine. SP+CQ=sulfadoxine-pyrimethamine chloroquine. AL=artemether-lumefantrine. Zongo and colleagues' numbers are based on actual drug exposures. Poespoprodjo and colleagues: only 64 of 408 DP recipients received two or more courses of DP.

References

    1. Lozano R, Naghavi M, Foreman K. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095–2128.
    1. Desai M, ter Kuile FO, Nosten F. Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis. 2007;7:93–104.
    1. World Health Organization . World Malaria Report 2015. WHO Press; Geneva, Switzerland: 2015.
    1. World Health Organization . Guidelines for the treatment of malaria. 3rd edn. World Health Organization; Geneva, Switzwerland: 2015.
    1. Smithuis F, Kyaw MK, Phe O. Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison. Lancet. 2006;367:2075–2085.
    1. Zongo I, Milligan P, Compaore YD. Randomized non-inferiority trial of dihydroartemisinin-piperaquine compared with sulfadoxine-pyrimethamine plus amodiaquine for SMC in Burkina Faso. Antimicrob Agents Chemother. 2015;59:4387–4396.
    1. Pekyi D, Ampromfi AA, Tinto H. Four artemisinin-based treatments in African pregnant women with malaria. N Engl J Med. 2016;374:913–927.
    1. Makanga M, Krudsood S. The clinical efficacy of artemether/lumefantrine (Coartem) Malar J. 2009;8(suppl 1):S5.
    1. Sinclair D, Zani B, Donegan S, Olliaro P, Garner P. Artemisinin-based combination therapy for treating uncomplicated malaria. Cochrane Database Syst Rev. 2009;3 CD007483.
    1. Dzinjalamala FK, Macheso A, Kublin JG. Association between the pharmacokinetics and in vivo therapeutic efficacy of sulfadoxine-pyrimethamine in Malawian children. Antimicrob Agents Chemother. 2005;49:3601–3606.
    1. Sinclair D, Donegan S, Isba R, Lalloo DG. Artesunate versus quinine for treating severe malaria. Cochrane Database Syst Rev. 2012;6 CD005967.
    1. Myint HY, Ashley EA, Day NP, Nosten F, White NJ. Efficacy and safety of dihydroartemisinin-piperaquine. Trans R Soc Trop Med Hyg. 2007;101:858–866.
    1. Agency EM. Eurartesim. 2013. (accessed May 16, 2015).
    1. Schwartz PJ, Stramba-Badiale M, Crotti L. Prevalence of the congenital long-QT syndrome. Circulation. 2009;120:1761–1767.
    1. Owens RC, Jr, Nolin TD. Antimicrobial-associated QT interval prolongation: pointes of interest. Clin Infect Dis. 2006;43:1603–1611.
    1. Lopez JA, Harold JG, Rosenthal MC, Oseran DS, Schapira JN, Peter T. QT prolongation and torsades de pointes after administration of trimethoprim-sulfamethoxazole. Am J Cardiol. 1987;59:376–377.
    1. Traebert M, Dumotier B. Antimalarial drugs: QT prolongation and cardiac arrhythmias. Expert opinion on drug safety. 2005;4:421–431.
    1. Darpo B, Nebout T, Sager PT. Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the international conference on harmonization of technical requirements for registration of pharmaceuticals for human use E14 guideline. J Clin Pharmacol. 2006;46:498–507.
    1. Manning J, Vanachayangkul V, Lon C. Randomized double-blind, placebo-controlled clinical trial of a two-day regimen of dihydroartemisinin-piperaquine for malaria prevention halted for concern over prolonged corrected QT tnterval. Antimicrob Agents Chemother. 2014;58:6056–6067.
    1. Wanzira H, Kakuru A, Arinaitwe E. Longitudinal outcomes in a cohort of Ugandan children randomized to artemether-lumefantrine versus dihydroartemisinin-piperaquine for the treatment of malaria. Clin Infect Dis. 2014;59:509–516.
    1. Pharmaceuticals S-T. Eurartemis: Summary of Product Characteristics [Brochure] 2011. (accessed Feb 16, 2016).
    1. Adjei A, Narh-Bana S, Amu A. Treatment outcomes in a safety observational study of dihydroartemisinin/piperaquine (Eurartesim®) in the treatment of uncomplicated malaria at public health facilities in four African countries. Malaria J. 2016;15:1–10.
    1. Borsini F, Crumb W, Pace S. In vitro cardiovascular effects of dihydroartemisin-piperaquine combination compared with other antimalarials. Antimicrob Agents Chemother. 2012;56:3261–3270.
    1. Liberati A, Altman DG, Tetzlaff J. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.
    1. Higgins J, Green S. The Cochrane handbook for systematic reviews of interventions. John Wiley & Sons; Chichester, UK: 2006.
    1. Wells G, Shae B, O'Connell D. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. 2014. (accessed May 26, 2015).
    1. Tagbor H, Antwi GD, Acheampong PR, Bart Plange C, Chandramohan D, Cairns M. Seasonal malaria chemoprevention in an area of extended seasonal transmission in Ashanti, Ghana: an individually randomised clinical trial. Trop Med Int Health. 2016;21:224–235.
    1. Rijken MJ, McGready R, Boel ME. Dihydroartemisinin-piperaquine rescue treatment of multidrug-resistant plasmodium falciparum malaria in pregnancy: a preliminary report. Am J Trop Med Hyg. 2008;78:543–545.
    1. Poespoprodjo JR, Fobia W, Kenangalem E. Dihydroartemisinin-piperaquine treatment of multidrug resistant falciparum and vivax malaria in pregnancy. PLoS One. 2014;9:e84976.
    1. Bigira V, Kapisi J, Clark TD. Protective Efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: a randomized controlled trial. PLoS Med. 2014;11:e1001689.
    1. Bojang K, Akor F, Bittaye O. A randomised trial to compare the safety, tolerability and efficacy of three drug combinations for intermittent preventive treatment in children. PLoS One. 2010;5:e11225.
    1. Cisse B, Cairns M, Faye E. Randomized trial of piperaquine with sulfadoxine-pyrimethamine or dihydroartemisinin for malaria intermittent preventive treatment in children. PLoS One. 2009;4:e7164.
    1. Kamya MR, Kapisi J, Bigira V. Efficacy and safety of three regimens for the prevention of malaria in young HIV-exposed Ugandan children: a randomized controlled trial. AIDS. 2014;28:2701–2709.
    1. Nankabirwa JI, Wandera B, Amuge P. Impact of intermittent preventive treatment with dihydroartemisinin-piperaquine on malaria in Ugandan schoolchildren: a randomized, placebo-controlled trial. Clin Infect Dis. 2014;58:1404–1412.
    1. Lwin KM, Phyo AP, Tarning J. Randomized, double-blind, placebo-controlled trial of monthly versus bimonthly dihydroartemisinin-piperaquine chemoprevention in adults at high risk of malaria. Antimicrob Agents Chemother. 2012;56:1571–1577.
    1. Desai M, Gutman J, L'Lanziva A. Intermittent screening and treatment or intermittent preventive treatment with dihydroartemisinin-piperaquine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for the control of malaria during pregnancy in western Kenya: an open-label, three-group, randomised controlled superiority trial. Lancet. 2015;386:2507–2519.
    1. Kakuru A, Jagannathan P, Muhindo M. Dihydroartemisinin-piperaquine for the prevention of malaria in pregnancy. New Engl J Med. 2016;374:928–939.
    1. Zani B, Gathu M, Donegan S, Olliaro PL, Sinclair D. Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria. Cochrane Database Syst Rev. 2014;1 CD010927.
Uncited Reference
    1. Sweeting M, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med. 2004;23:1351–1375.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren